MIL-62 is under clinical development by Beijing Mabworks Biotech and currently in Phase II for Splenic Marginal Zone B-Cell Lymphoma.

Chlorogenic acid is under clinical development by Sichuan J.Z. Bio-chemical Science and Technology Development and currently in Phase II for Non-Small Cell Lung Cancer.

(Nivolumab + relatlimab) is under clinical development by Bristol-Myers Squibb and currently in Phase III for Non-Small Cell Lung Cancer.

BARS-13 is under clinical development by Beijing Advaccine Biotechnology and currently in Phase II for Respiratory Syncytial Virus (RSV) Infections.

BI-765049 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Non-Small Cell Lung Cancer.

ANP-390 is under clinical development by AlphaNavi Pharma and currently in Phase I for Peripheral Neuropathic Pain.

NUC-7738 is under clinical development by NuCana and currently in Phase II for B-Cell Non-Hodgkin Lymphoma. According to GlobalData, Phase II drugs for B-Cell Non-Hodgkin Lymphoma have a 36% phase ...

OMTX-705 is under clinical development by Oncomatryx Biopharma and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase I drugs for Ovarian Cancer have a 73% phase transition ...

Curcumin glucuronide is under clinical development by TheraBioPharma and currently in Phase III for Coronavirus Disease 2019 (COVID-19).

GT-0002X is under clinical development by Gene Therapy Research Institution and currently in Phase II for Parkinson's Disease.

Bisantrene is under clinical development by Race Oncology and currently in Phase II for Refractory Acute Myeloid Leukemia.

APX-3330 is under clinical development by Opus Genetics and currently in Phase II for Non-Proliferative Diabetic Retinopathy (NPDR).